EUCTR2022-002839-66-SK进行中（未招募）1 期
An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •For all participants:
- •1. Have completed the Week 24 visit of the feeder study.
- •For participants assigned to the Open-label Treatment Cohort:
- •1. Do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
- •2. Did not permanently discontinue study drug
- •Additional inclusion criteria are defined in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 162
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •For all participants:
- •1. In the Investigator's judgement, the benefits of entry in the study do not outweigh the risk.
研究者
相似试验
招募中
1 期
Extension Study to Assess Batoclimab in Participants with TED.Thyroid Eye Disease (TED)CTIS2024-512650-21-00Immunovant Sciences GmbH180
进行中（未招募）
1 期
Extension Study to Assess Batoclimab in Participants with TEDThyroid Eye Disease (TED)MedDRA version: 23.1Level: LLTClassification code 10084358Term: Thyroid eye diseaseSystem Organ Class: 10015919 - Eye disordersEUCTR2022-002839-66-PLImmunovant Sciences, GmbH180
进行中（未招募）
1 期
Extension Study to Assess Batoclimab in Participants with TEDEUCTR2022-002839-66-HUImmunovant Sciences, GmbH180
进行中（未招募）
1 期
Extension Study to Assess Batoclimab in Participants with TEDThyroid Eye Disease (TED)MedDRA version: 23.1Level: LLTClassification code 10084358Term: Thyroid eye diseaseSystem Organ Class: 10015919 - Eye disordersEUCTR2022-002839-66-BEImmunovant Sciences, GmbH180
招募中
1 期
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studies.Thyroid eye diseaseMedDRA version: 20.1Level: PTClassification code: 10060742Term: Endocrine ophthalmopathy Class: 100000004853MedDRA version: 23.1Level: LLTClassification code: 10084358Term: Thyroid eye disease Class: 100000004848CTIS2023-507350-33-00Viridian Therapeutics S.à.r.l.149